Why Is Integra LifeSciences (IART) Stock Down -19.76% Today?
Key Takeaways
- IART shares plunged roughly 19.76% in Friday's session, falling from a prior close of $16.09 to about $12.91.
- Primary catalyst: The company cut its full-year 2026 revenue and adjusted EPS guidance following July flooding at its Cincinnati manufacturing facility.
- Secondary driver: Integra also announced a proposed $600 million seven-year Senior Secured Term Loan B as part of a broader debt refinancing.
- Broader context: The move was company-specific, diverging sharply from a firmer broader equity market.
- What traders are watching next: Integra's full third-quarter report and conference call, expected later in October.
Opening Summary
Integra LifeSciences Holdings Corporation (IART), a Princeton, New Jersey-based medical technology company focused on neurosurgery, tissue reconstruction, and specialty surgical technologies, saw its shares tumble on Friday. The stock fell from a prior-session close of $16.09 to roughly $12.91, a decline of approximately 19.76%. The sell-off was driven by the company's decision to lower its full-year 2026 outlook, citing the ongoing operational and financial fallout from flooding at its Cincinnati manufacturing plant, alongside the announcement of a sizeable debt refinancing transaction.
Guidance Cut Driven by Cincinnati Facility Flooding
The dominant catalyst behind the decline was a downward revision to Integra's full-year 2026 financial guidance. The company reduced its reported revenue outlook to a range of $1.634 billion to $1.654 billion, down from its prior range of $1.654 billion to $1.695 billion. Adjusted earnings per diluted share guidance was lowered to $2.30 to $2.40, from a previous range of $2.40 to $2.50. Both revisions came in below the Street's expectations, which had modeled full-year revenue near $1.67 billion and adjusted EPS around $2.46.
The revision traces back to flooding at the Cincinnati facility in July 2026, which damaged portions of the site, equipment, inventory, and other assets. Management now estimates the supply disruption reduced third-quarter revenue by approximately $7 million and expects an additional fourth-quarter revenue impact of roughly $15 million to $20 million. A return to full manufacturing operations at the site is not anticipated until the second quarter of 2027, extending the disruption far longer than some investors had hoped.
Preliminary Third-Quarter Results Disappoint
Alongside the guidance update, Integra provided preliminary third-quarter results that landed below analyst estimates. The company expects third-quarter revenue of approximately $410 million to $412 million and adjusted earnings per diluted share of $0.55 to $0.59. Wall Street had been looking for revenue of about $416.3 million and adjusted EPS of $0.56, meaning the top-line range fell short of consensus and stoked concern that the flooding impact may be broader than initially anticipated.
Chief Executive Officer Stuart Essig acknowledged the disruption directly, noting that the company has gained "additional visibility into the recovery timeline and production ramp." While he stressed continued strength in cash generation — including more than $85 million of operating cash flow expected in the third quarter and $190 million to $200 million for the full year — the lowered outlook outweighed those positives in the market's immediate reaction.
Debt Refinancing Adds to the Overhang
Compounding the pressure, Integra separately announced the launch of a proposed $600 million seven-year Senior Secured Term Loan B as part of a broader refinancing of its existing indebtedness. The company said the proceeds would be used to refinance existing debt, extend maturities, and preserve financial flexibility. While framed by management as a move toward disciplined capital allocation and deleveraging, the disclosure of additional leverage layered on top of the guidance cut and weighed on sentiment, adding to the sell-off.
Market Context and Trading Activity
The sharp decline in IART stood out as a company-specific event rather than a reflection of sector or macro weakness. Broader equity indices traded higher on the day, meaning the medical device maker's plunge was driven almost entirely by its own corporate news. Trading activity was elevated relative to recent sessions as investors repriced the stock following the revised outlook, and the shares fell well below their 50-day moving average, marking a fresh multi-month low and extending a retreat from the stock's 52-week high near $20.49.
What Comes Next for IART
Looking ahead, the focus shifts to Integra's complete third-quarter report and investor conference call, which the company indicated will be held later in October. Investors will be watching for additional color on the Cincinnati facility's recovery timeline, the pace of insurance recoveries, and whether supply disruptions continue to pressure the Specialty Surgical Technologies portfolio into 2027. The company has said it expects property and business interruption insurance to mitigate a substantial portion of the earnings impact, but the timing and magnitude of those recoveries remain a key uncertainty. Broader execution risks — including product availability, regulatory and quality remediation efforts, and the concentrated nature of its product portfolio — will also remain in focus as the market assesses whether the lowered guidance fully captures the disruption.
Trending AI Robots
For traders seeking a more systematic approach to navigating volatile markets, Trending AI Robots from Tickeron offers a curated view of the platform's strongest-performing automated trading strategies. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only those demonstrating the strongest performance under current market conditions are featured in this dedicated section. The bots vary by strategy, timeframe, performance metrics, and traded symbols, giving investors a range of options aligned with their own objectives. Explore the Trending AI Robots page to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IART's Stochastic Oscillator slumps into oversold zone
The Stochastic Oscillator for IART moved into oversold territory on October 05, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +3.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where IART advanced for three days, in 181 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
IART may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IART as a result. In 75 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for IART turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 32 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IART declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for IART entered a downward trend on September 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. IART’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.213) is normal, around the industry mean (10.853). P/E Ratio (66.483) is within average values for comparable stocks, (98.910). Projected Growth (PEG Ratio) (0.669) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.751) is also within normal values, averaging (39.828).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IART’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of medical devices, implants and biomaterials
Industry MedicalNursingServices
Advertisement